Mayne hit by misleading drug safety claims from the FDA ahead of $430M buyout
Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral birth control pill in a presentation, triggering an untitled letter.
Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral birth control pill in a presentation, triggering an untitled letter.
